Zealand Pharma A/S (ZEAL) 2020年CSR报告「NASDAQ」.pdf

《Zealand Pharma A/S (ZEAL) 2020年CSR报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Zealand Pharma A/S (ZEAL) 2020年CSR报告「NASDAQ」.pdf（16页珍藏版）》请在三个皮匠报告上搜索。

1、Company reg.no.20045078Growing as a leader in peptide therapeuticsZealand Pharma Corporate Responsibility Report 2020ContentsCorporate Responsibility Report 2020Changing lives 3Transforming peptides 4Our business model 5Focus on Corporate Responsibility 6Our People 7Quality 10Patients 11Environment

2、13Ethics 14About this ReportThis statutory report on corporate social and environmental responsi-bility is for the financial year 2020,cf.section 99a and 99b of the Danish Financial Statements Act.This report is a supplement to the managements review in the Annual Report 2020 covering the period Jan

3、uary 1 to December 31,2020.2Zealand Pharma Corporate Responsibility Report 2020Changing livesWe work every day with patient communities and thought leaders to change the lives of people with severe medical conditions.Our ambition is to be a world leader in treating specialty metabolic and gastrointe

4、stinal diseases.We intend to deliver best in-class treatment options that meet patient medical needs and ease the burden on the health care system.We are passionate about changing the lives of people with severe medical conditions through targeted development of next generation peptide therapeutics.

5、There are over 300 million people living with one or more of over 6,000 identified rare diseases around the world1,each supported by family,friends and a team of caregivers that make up the rare disease community.Many of these diseases are life threatening,with no available therapy to help these pat

6、ient groupsPeptides have proven to be effective drugs in a number of different diseases,with significant untapped potential across many therapy areas.SDG 3:Ensure healthy lives and promote well-being for all at all agesFind out more about Zealand at INSERM(Institut national de la sant et de la reche